INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2014

An analysis suggests the FDA's proposed ban on artificial trans fats provides public health gains at low to no cost and is economically sensible.

This commentary compared the benefits and costs of the US Food and Drug Administration's proposed ban on artificial trans fats against other public health risks and interventions. It assessed population disease burden, individual mortality risks, and cost-effectiveness per quality-adjusted life-year (QALY) gained. The population impact of remaining trans fats was small relative to many other risks, but lifetime individual risks were comparable to other notable risks. The ban was found to achieve public health gains at low to no cost, making it sensible from an economic efficiency perspective.

Study type
Economic and risk analysis commentary
Who was studied
US population
What was measured
Population disease burden (QALYs), individual mortality risks, cost-effectiveness

THE PAPER

FDA's proposed ban on trans fats: How do the costs and benefits stack up?

Cohen JT. Clin Ther, 2014.

PubMed 24636817 ↗DOI 10.1016/j.clinthera.2014.01.007 ↗

Nutrients & adequacyFood safety & contaminants

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.